FIG 8.

Loss of SET1 in C. glabrata clinical isolates SM1 and resistant strain SM3 results in increased azole sensitivity. (A to C) Fivefold serial dilution spot assays of the indicated C. glabrata clinical isolates were grown on SC plates with or without fluconazole and/or 20 μg/mL ergosterol. (D) RFU were measured as output in a Nile red assay to determine the amount of drug efflux in the indicated SM1 and SM3 clinical isolates treated with 64 or 256 μg/mL fluconazole. A Cgpdr1Δ strain was used as a control. Data were analyzed from ≥ 3 biological replicates with three technical replicates each. (E and F) Expression of ERG11 was determined from the indicated SM1 and SM3 clinical isolates treated with 64 and 256 μg/mL fluconazole, respectively, for 3 h by qRT-PCR analysis. Gene expression analysis was set relative to the untreated wild-type and expression was normalized to RDN18 mRNA levels. Data were analyzed from ≥3 biological replicates with three technical replicates each. Error bars represent the SD. Statistics were determined using the GraphPad Prism Student t test, version 9.2.0. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.